USAN drug names under consideration

USAN Council's statement on the use of USAN as domain names is that a name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names website shall be the effective equivalent of an intellectual property right for the relevant entities.

Visit United States Adopted Names FAQ to learn more.

Comments or protests should be addressed to Stephanie Shubat, USAN program director, American Medical Association, 330 North Wabash Ave., Suite 39300, Chicago, Illinois 60611, or via email: [email protected]. 

In order to ensure your "under consideration" USAN domain name is available, you should consider purchasing the .com, .net and .org domain names of the USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following names for the drugs described are "under consideration" by the USAN Council:

Atirmociclib: Antineoplastic

Etalanetug: Treatment of Alzheimer’s disease

Frespaciguat: Treatment of pulmonary hypertension

Imneskibart: Antineoplastic

Imzokitug: Antineoplastic

Lunlekitug: Treatment of cardiovascular and inflammatory diseases

Mevrometostat: Antineoplastic 

Midafilcon b: Contact lens material

Naxtarubicin: Antineoplastic

Neldaleucel: Treatment of various hematologic malignancies [such as non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL)] and solid tumors

Nelitolimod: Antineoplastic

Nilotinib laurylsulfate: Treatment of myeloid leukemia

Ocadusertib: Treatment of autoimmune and inflammatory diseases, such as, psoriasis, rheumatoid arthritis (RA) or inflammatory bowel diseases (IBD)

Olomorasib: Antineoplastic

Pebezertinib: Antineoplastic

Ribitol: Treatment of limb-girdle muscular dystrophy type 2I/R9, FKRP-related (LGMD2I/R9)

Rilogrotug: Treatment of cachexia in cancer patients with elevated GDF-15 levels

Ruxoprubart: Treatment of complement mediated diseases

Salanersen: Treatment of spinal muscular atrophy (SMA)

Suzetrigine: Treatment of acute and neuropathic pain

Zelebrudomide: Antineoplastic

Bafisontamab: Antineoplastic

Brilaroxazine: Treatment of schizophrenia

Falbikitug: Antineoplastic

Flizasertib: Treatment of inflammatory and autoimmune diseases and disorders

Golcadomide hydrochloride: Antineoplastic

Idrebormilast: Topical treatment of atopic dermatitis and plaque psoriasis

Maplirpacept: Treatment of advanced relapsed or refractory lymphoma or myeloma

Naporafenib: Treatment of cancer

Palazestrant: Treatment of breast cancer

Pritelivir: Treatment and suppression of herpes simplex virus (HSV) infection

Rinvecalinase alfa: Treatment of ischemic related diseases and chronic kidney diseases (CKD)

Risvodetinib: Treatment of Parkinson’s disease

Tarperprumig: Antineoplastic

Temtokibart: Treatment of moderate to severe atopic dermatitis (AD)

Ulviprubart: Treatment of IgA nephropathy in adults

Ulixacaltimide: Reducing the risk of major adverse cardiovascular events in adults

Vonsetamig: Treatment of inclusion body myositis (IBM) and T cell large granular lymphocytic leukemia (T-LGLL)

Acetylcysteine zidrimer: Treatment of neuroinflammation in patients with ALS

Adalimumab fosimdesonide: Immunologic agent

Baxdrostat: Treatment of hypertension associated with inappropriately elevated aldosterone levels

Bersiporocin: Treatment of idiopathic pulmonary fibrosis (IPF), systematic sclerosis (SSc) and associated complications

Denecimig: Prevention of bleeding episodes in patients with hemophilia

Eneboparatide: Treatment of Hypoparathyroidism (HP)

Ivonescimab: Treatment of Duchenne Muscular Dystrophy (DMD) and Polycythemia Vera (PV)

Linavonkibart: Antineoplastic

Livmoniplimab: Antineoplastic

Minizasolmin: Treatment of Parkinson’s disease

Nelutroctiv: For the improvement of cardiac systolic function

Povetacicept: Treatment of inflammatory conditions where b cell activating factor (BAFF) and/or a proliferation inducting ligand (APRIL) may be implicated  

Tividenofusp alfa: Treatment of mudopolysaccharidosis type II (MPS II; Hunter Syndrome)

Verzistobart: Antineoplastic

Vociprotafib: Antineoplastic

Zigakibart: Treatment of IgA nephropathy in adults

Ziltivekimab: Reducing the risk of major adverse cardiovascular events in adults